Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Exposures

The legacy context of general health and science information often addresses broad public concerns, such as the impact of lifestyle changes during the COVID-19 pandemic on alcohol consumption and well-being. This heritage emphasizes maintaining healthy habits and understanding the physical and psychological effects of substances when used excessively. Such discussions naturally lead to a focus on how specific exposures can influence health outcomes, particularly when patterns of use shift under stress or altered circumstances. Transitioning from this general health perspective, the concern now narrows to a specific occupational exposure scenario. In mass production environments, workers may encounter various chemical agents or pharmaceuticals as part of their duties, raising questions about potential health risks. One such substance of interest is Fosamax, a bisphosphonate commonly prescribed for bone conditions. The query here centers on whether occupational exposure to Fosamax could be linked to osteonecrosis of the jaw, a condition affecting the jawbone. This pivot moves from broad health awareness to a targeted inquiry about workplace-related risks, without delving into disease mechanisms or citing evidence, but rather setting the stage for further investigation into exposure pathways and safety protocols.

Fosamax and Osteonecrosis of the Jaw: The Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or be triggered by dental procedures. Clinical presentation and diagnosis of ONJ typically involve exposed bone in the maxillofacial region that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental surgery. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other jaw pathologies. The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits osteoclast-mediated bone resorption. This suppression of bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental infections or trauma. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high remodeling rate and unique vascular supply may make it particularly vulnerable to bisphosphonate-induced suppression of remodeling.

Risk Factors and Clinical Considerations

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients require careful evaluation of the timeline between exposure and documented harm. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in clinical trials was low and not significantly different from placebo, indicating that other factors may contribute to its development. For patients who develop ONJ, management includes discontinuation of Fosamax if severe symptoms develop, along with conservative dental care, antibiotics, and oral rinses. The label advises that most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the recurrence of symptoms upon rechallenge with bisphosphonates highlights the need for careful risk-benefit assessment in patients with a history of ONJ. In summary, Fosamax is associated with osteonecrosis of the jaw, with a plausible mechanistic link through suppression of bone remodeling. The prescribing information includes warnings about this risk, and known risk factors include dental procedures, cancer, and concomitant therapies. The timeline for onset can vary, and discontinuation of the drug may lead to symptom resolution. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis prevention against the potential risk of ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption, and its use has been associated with osteonecrosis of the jaw (ONJ). The condition involves exposed, non-healing bone in the jaw, often triggered by dental procedures. The mechanistic link is suppression of bone remodeling, impairing repair of microdamage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use may also increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and managed in patients taking Fosamax?

Diagnosis is based on clinical examination and imaging, with exposed bone persisting for more than eight weeks. Management includes discontinuation of Fosamax if severe symptoms develop, along with conservative dental care, antibiotics, and oral rinses. Most patients experience relief after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.